Epidemiology & Risk Factors

  • Primary Raynaud Phenomenon (Raynaud Disease):
    • Most common (>80% of cases).
    • Typically females aged 15–30 years.
    • No underlying systemic disease, normal physical exam, normal nailfold capillaries, negative inflammatory markers/autoantibodies.
  • Secondary Raynaud Phenomenon (Raynaud Syndrome):
    • Typically onset at >30–40 years of age; equal male/female prevalence.
    • Connective Tissue Diseases (CTD): Systemic Sclerosis (SSc / Scleroderma) (>90% of SSc pts), SLE, Mixed Connective Tissue Disease (MCTD), Sjögren syndrome, Dermatomyositis.
    • Vascular / Occlusive: Thromboangiitis obliterans (Buerger disease), atherosclerosis, thoracic outlet syndrome (TOS).
    • Occupational / Physical: Repeated vibration trauma (e.g., jackhammer, chainsaw use), frostbite.
    • Medications / Drugs: Beta-blockers, ergotamines/triptans, stimulants/amphetamines, cocaine, chemotherapeutics (bleomycin, cisplatin), nicotine.
    • Hematologic: Cryoglobulinemia, cold agglutinin disease, paraproteinemia.

Diagnosis

  • Initial Evaluation:
    • Clinical diagnosis based on history of cold/stress-induced episodic digital color changes.
    • Key goal: Differentiate Primary vs. Secondary RP.
  • Initial / Bedside Test:
    • Nailfold Capillaroscopy:
      • Normal parallel, hairpin loops -> Primary RP.
      • Dilated, tortuous, or dropped-out (avascular areas) loops -> Secondary RP (especially SSc/CTD).
  • Key Labs (indicated if secondary RP suspected or age >30):
    • Initial Screening: ANA, ESR / CRP, CBC, CMP, Urinalysis. c
    • Confirmatory / Specific Autoantibodies (if ANA positive):
      • Anti-Scl-70 (Anti-topoisomerase I) & Anti-Centromere: Systemic Sclerosis (diffuse vs. limited/CREST).
      • Anti-dsDNA, Anti-Smith: SLE.
      • Anti-U1-RNP: Mixed Connective Tissue Disease (MCTD).
      • Anti-Ro/SSA, Anti-La/SSB: Sjögren syndrome.
      • Cryoglobulins / Serum protein electrophoresis (SPEP): If associated with purpura, arthralgias, or renal disease.
  • Vascular Imaging / Testing:
    • Indicated if asymmetric presentation, absent pulses, or suspicion of proximal macrovascular occlusion.
    • Arterial Duplex US or CTA / MRA / Digital Plethysmography.